Literature DB >> 34089365

Short- and long-term outcomes of immediate breast reconstruction surgery after neoadjuvant chemotherapy.

Toshiyuki Ishiba1, Tomoyuki Aruga2, Hiromi Miyamoto2, Sakiko Ishihara2, Miyako Nara2, Mio Adachi2, Yuichi Kumaki2, Chiaki Saita2, Mai Onishi2, Risa Goto2, Naoko Iwamoto2, Rika Yonekura2, Yayoi Honda2, Miwako Fujii3, Shoichi Tomita3, Shinichiro Horiguchi4, Goshi Oda5, Tsuyoshi Nakagawa5, Tomoyuki Fujioka6, Yasunobu Terao3.   

Abstract

PURPOSE: Immediate breast reconstruction (IBR) is a standard option for breast cancer patients, although its utility in patients with advanced breast cancer requiring neoadjuvant chemotherapy (NAC) is debatable. We assessed the short-term complications and long-term prognosis of IBR after NAC.
METHODS: We retrospectively analyzed 1135 patients with IBR and/or NAC between 2010 and 2018, 43 of whom underwent IBR after NAC.
RESULTS: Twenty-five patients underwent reconstruction with a tissue expander (TE) followed by silicon breast implantation, 5 with a latissimus dorsi muscle transfer flap, and 13 with a deep inferior epigastric perforator flap. Complete surgical resection with a free margin confirmed by a pathological assessment was achieved in all patients. The evaluation of the short-term complications indicated no cases of total flap necrosis, two cases of partial flap necrosis, and one case of wound infection. Only one case required postponement of subsequent therapy due to partial flap necrosis. A long-term evaluation indicated no local recurrence, although distant metastasis was observed in 4 cases, 3 patients died, and TE removal after post-mastectomy radiotherapy (PMRT) was performed in 2 of 11 TE cases.
CONCLUSION: IBR may be a viable option in patients with advanced breast cancer who achieve complete surgical resection after NAC.
© 2021. Springer Nature Singapore Pte Ltd.

Entities:  

Keywords:  Breast cancer; Complications; Immediate breast reconstruction; Neoadjuvant chemotherapy

Mesh:

Year:  2021        PMID: 34089365     DOI: 10.1007/s00595-021-02316-3

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  5 in total

1.  Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?

Authors:  Gaetano Aurilio; Vincenzo Bagnardi; Rossella Graffeo; Franco Nolè; Jean Yves Petit; Marzia Locatelli; Stefano Martella; Marco Iera; Piercarlo Rey; Giuseppe Curigliano; Nicole Rotmensz; Elisabetta Munzone; Aron Goldhirsch
Journal:  Anticancer Res       Date:  2014-11       Impact factor: 2.480

2.  Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011.

Authors:  Junichi Kurebayashi; Yasuo Miyoshi; Takashi Ishikawa; Shigehira Saji; Tomoharu Sugie; Takashi Suzuki; Shunji Takahashi; Miwako Nozaki; Hiroko Yamashita; Yutaka Tokuda; Seigo Nakamura
Journal:  Breast Cancer       Date:  2015-03-11       Impact factor: 4.239

3.  Postmastectomy radiation therapy and breast reconstruction with autologous tissue.

Authors:  Yasunobu Terao; Koichiro Taniguchi; Miwako Fujii; So Moriyama
Journal:  Breast Cancer       Date:  2017-02-22       Impact factor: 4.239

4.  Does neoadjuvant chemotherapy for breast cancer increase complications during immediate breast reconstruction?

Authors:  Ying Liu; Hiroki Mori; Yuiro Hata
Journal:  J Med Dent Sci       Date:  2009-03

Review 5.  Clinical outcomes of patients after nipple-sparing mastectomy and reconstruction based on the expander/implant technique.

Authors:  Uhi Toh; Miki Takenaka; Nobutaka Iwakuma; Yoshito Akagi
Journal:  Surg Today       Date:  2020-11-13       Impact factor: 2.549

  5 in total
  1 in total

1.  Latissimus dorsi myocutaneous flap repair is effective after neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Lu Li; Yue Yang; Wang Li; Xian Zhao; Jia He; Shuo Mei; Xuejun Guo; Xibin Zhang; Jianghua Ran
Journal:  World J Surg Oncol       Date:  2022-04-27       Impact factor: 3.253

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.